{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:26:33Z","timestamp":1791559593691,"version":"4.3.4"},"reference-count":37,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15472","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:20:57Z","timestamp":1769520057000},"page":"1-12","source":"Crossref","is-referenced-by-count":4,"title":["Immune microenvironment and treatment response of dMMR gastric cancer: Heterogeneity and implications for immunotherapy"],"prefix":"10.3892","volume":"31","author":[{"given":"Liping","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Southern University of Science and Technology Hospital, Shenzhen, Guangdong 518055, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinliang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Southern University of Science and Technology Hospital, Shenzhen, Guangdong 518055, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxing","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Southern University of Science and Technology Hospital, Shenzhen, Guangdong 518055, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Southern University of Science and Technology Hospital, Shenzhen, Guangdong 518055, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"key20260206093219_b1-ol-31-3-15472","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20260206093219_b2-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21147\/j.issn.1000-9604.2021.01.02","article-title":"Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: Findings from Global Burden of Disease Study","volume":"33","author":"Zhang","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"key20260206093219_b3-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"S2618","DOI":"10.1200\/JCO.2023.41.16_suppl.2618","article-title":"Genomic landscapes to characterize mismatch-repair deficiency (dMMR)\/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20260206093219_b4-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"key20260206093219_b5-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1177\/17588359241231259","article-title":"Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: A systematic review and meta-analysis","volume":"16","author":"Petrelli","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"key20260206093219_b6-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers14041054","article-title":"The new era of immunotherapy in gastric cancer","volume":"14","author":"Takei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260206093219_b7-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"e16121","DOI":"10.1200\/JCO.2024.42.16_suppl.e16121","article-title":"Immunotherapy-based therapy versus chemotherapy for the neoadjuvant treatment of locally advanced dMMR\/MSI-H gastric cancer","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260206093219_b8-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1291117","DOI":"10.3389\/fimmu.2023.1291117","article-title":"Research progress on the immune microenvironment and immunotherapy in gastric cancer","volume":"14","author":"Mou","year":"2023","journal-title":"Front Immunol"},{"key":"key20260206093219_b9-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite Instability-High solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20260206093219_b10-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"122846","DOI":"10.1016\/j.biomaterials.2024.122846","article-title":"Tertiary lymphoid structure formation induced by LIGHT-engineered and photosensitive nanoparticles-decorated bacteria enhances immune response against colorectal cancer","volume":"314","author":"Hu","year":"2025","journal-title":"Biomaterials"},{"key":"key20260206093219_b11-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.smim.2022.101703","article-title":"Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?","volume":"65","author":"Fridman","year":"2023","journal-title":"Semin Immunol"},{"key":"key20260206093219_b12-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","article-title":"Clinical guidelines for the diagnosis and treatment of gastric cancer","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun"},{"key":"key20260206093219_b13-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"key20260206093219_b14-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"key20260206093219_b15-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41698-021-00172-5","article-title":"A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer","volume":"5","author":"Jiao","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"key20260206093219_b16-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","article-title":"Genetic predictors of response to systemic therapy in esophagogastric cancer","volume":"8","author":"Janjigian","year":"2018","journal-title":"Cancer Discov"},{"key":"key20260206093219_b17-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a Histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"key20260206093219_b18-ol-31-3-15472","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2017","edition":"8th edition"},{"key":"key20260206093219_b19-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20260206093219_b20-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch Repair\/Microsatellite Instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA Phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20260206093219_b21-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/CMR.0000000000000330","article-title":"The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: How to manage heterogeneity?","volume":"27","author":"Obeid","year":"2017","journal-title":"Melanoma Res"},{"key":"key20260206093219_b22-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10585-021-10091-1","article-title":"Cancer neoantigens as potential targets for immunotherapy","volume":"39","author":"Ma","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"key20260206093219_b23-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"key20260206093219_b24-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"key20260206093219_b25-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/cancers13133107","article-title":"PD-L1 expression associated with Epstein-Barr virus status and Patients' survival in a large cohort of gastric cancer patients in northern brazil","volume":"13","author":"De F\u00e1tima Aquino Moreira-Nunes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260206093219_b26-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients With First-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20260206093219_b27-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2024.12.020","article-title":"Pembrolizumab in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) and non-MSI-H\/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results","volume":"193","author":"O'Malley","year":"2025","journal-title":"Gynecol Oncol"},{"key":"key20260206093219_b28-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20260206093219_b29-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"e002467","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20260206093219_b30-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/labmed\/lmae090","article-title":"Correlation of the abundance of MDSCs, Tregs, PD-1, and PD-L1 with the efficacy of chemotherapy and prognosis in gastric cancer","volume":"56","author":"Li","year":"2025","journal-title":"Lab Med"},{"key":"key20260206093219_b31-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1186\/s12885-023-11447-4","article-title":"Wnt\/\u03b2-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Cancer"},{"key":"key20260206093219_b32-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00262-012-1321-6","article-title":"Implication of the \u03b22-microglobulin gene in the generation of tumor escape phenotypes","volume":"61","author":"Bernal","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20260206093219_b33-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.31557\/APJCP.2020.21.11.3393","article-title":"TGF-\u03b2 enhances the Anti-inflammatory effect of Tumor-infiltrating CD33+11b+HLA-DR Myeloid-derived suppressor cells in gastric cancer: A possible relation to MicroRNA-494","volume":"21","author":"Moaaz","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20260206093219_b34-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"P102","DOI":"10.1007\/s10330-020-0470-0","article-title":"Future of targeted therapy for gastrointestinal cancer: Claudin 18.2","volume":"17","author":"Niu","year":"2021","journal-title":"Oncol Transl Med"},{"key":"key20260206093219_b35-ol-31-3-15472","first-page":"64","article-title":"Claudin18.2-targeted cancer theranostics","volume":"13","author":"Zhang","year":"2023","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"key20260206093219_b36-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"key20260206093219_b37-ol-31-3-15472","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:32:29Z","timestamp":1770363149000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15472","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}